Gynecologic Oncology | Specialty

Dr. O’Malley on the Rationale to Evaluate Balstilimab/Zalifrelimab in Cervical Cancer

October 6th 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Dr. Naumann on the Evolution of Immunotherapy in Endometrial Cancer

October 5th 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Monk Reviews Transformative KEYNOTE-826 Data in Cervical Cancer and Next Steps for Research

October 5th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

FDA Grants Priority Review to Cemiplimab for Advanced Cervical Cancer

September 28th 2021

The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.

Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

September 23rd 2021

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.

FDA Approves Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

September 20th 2021

The FDA has granted an accelerated approval to tisotumab vedotin for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Balstilimab Plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Pembrolizumab/Chemo With or Without Bevacizumab May Represent New Frontline SOC in Cervical Cancer

September 18th 2021

The addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates in patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Monk on Transformative KEYNOTE-826 Data in Frontline Cervical Cancer

September 18th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Olaparib Rechallenge Improves PFS in Relapsed Ovarian Cancer Previously Treated With PARP Inhibition

September 17th 2021

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies

September 16th 2021

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Tisotumab Vedotin–Based Combos Demonstrate Antitumor Activity in Recurrent/Metastatic Cervical Cancer

September 15th 2021

Treatment with the antibody-drug conjugate tisotumab vedotin in combination with bevacizumab, pembrolizumab, or carboplatin was tolerable and elicited encouraging preliminary antitumor activity in patients with recurrent or metastatic cervical cancer.

Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer

September 7th 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Dr. Eskander on the Utility of Lymphadenectomy in Endometrial Cancer

August 25th 2021

Ramez N. Eskander, MD, discusses the utility of lymphadenectomy in patients with endometrial cancer.

Transvaginal Ultrasound Misses Mark on Screening Endometrial Cancer in Black Women

August 20th 2021

The use of transvaginal ultrasonography to measure the need for diagnostic testing of endometrial cancer missed almost 5 times more endometrial cancer cases in Black women compared with those in White women.

Dr. Robert L. Coleman discusses Rubraca® (rucaparib) for 2L Maintenance Treatment

August 18th 2021